281 related articles for article (PubMed ID: 24792721)
1. Inhibiting RORγt/Th17 axis for autoimmune disorders.
Isono F; Fujita-Sato S; Ito S
Drug Discov Today; 2014 Aug; 19(8):1205-11. PubMed ID: 24792721
[TBL] [Abstract][Full Text] [Related]
2. Targeting Th17 cells in autoimmune diseases.
Yang J; Sundrud MS; Skepner J; Yamagata T
Trends Pharmacol Sci; 2014 Oct; 35(10):493-500. PubMed ID: 25131183
[TBL] [Abstract][Full Text] [Related]
3. Identification of Tetraazacyclic Compounds as Novel Potent Inhibitors Antagonizing RORγt Activity and Suppressing Th17 Cell Differentiation.
Ding Q; Zhao M; Yu B; Bai C; Huang Z
PLoS One; 2015; 10(9):e0137711. PubMed ID: 26368822
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.
Guendisch U; Weiss J; Ecoeur F; Riker JC; Kaupmann K; Kallen J; Hintermann S; Orain D; Dawson J; Billich A; Guntermann C
PLoS One; 2017; 12(11):e0188391. PubMed ID: 29155882
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present).
Sun N; Guo H; Wang Y
Expert Opin Ther Pat; 2019 Sep; 29(9):663-674. PubMed ID: 31403347
[No Abstract] [Full Text] [Related]
7. Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Fasching P; Stradner M; Graninger W; Dejaco C; Fessler J
Molecules; 2017 Jan; 22(1):. PubMed ID: 28098832
[TBL] [Abstract][Full Text] [Related]
8. RORs in autoimmune disease.
Chang MR; Rosen H; Griffin PR
Curr Top Microbiol Immunol; 2014; 378():171-82. PubMed ID: 24728598
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds.
Ding Q; Zhao M; Bai C; Yu B; Huang Z
BMC Immunol; 2015 May; 16():32. PubMed ID: 26021566
[TBL] [Abstract][Full Text] [Related]
10. Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.
Tang L; Yang X; Liang Y; Xie H; Dai Z; Zheng G
Front Immunol; 2018; 9():1210. PubMed ID: 29899748
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.
Fujita-Sato S; Ito S; Isobe T; Ohyama T; Wakabayashi K; Morishita K; Ando O; Isono F
J Biol Chem; 2011 Sep; 286(36):31409-17. PubMed ID: 21733845
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
[TBL] [Abstract][Full Text] [Related]
13. Targeting Th17 Cells with Small Molecules and Small Interference RNA.
Lin H; Song P; Zhao Y; Xue LJ; Liu Y; Chu CQ
Mediators Inflamm; 2015; 2015():290657. PubMed ID: 26792955
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors of RORγt: targeting Th17 cells and other applications.
Huh JR; Littman DR
Eur J Immunol; 2012 Sep; 42(9):2232-7. PubMed ID: 22949321
[TBL] [Abstract][Full Text] [Related]
15. Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.
Smith SH; Peredo CE; Takeda Y; Bui T; Neil J; Rickard D; Millerman E; Therrien JP; Nicodeme E; Brusq JM; Birault V; Viviani F; Hofland H; Jetten AM; Cote-Sierra J
PLoS One; 2016; 11(2):e0147979. PubMed ID: 26870941
[TBL] [Abstract][Full Text] [Related]
16. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity.
Huh JR; Leung MW; Huang P; Ryan DA; Krout MR; Malapaka RR; Chow J; Manel N; Ciofani M; Kim SV; Cuesta A; Santori FR; Lafaille JJ; Xu HE; Gin DY; Rastinejad F; Littman DR
Nature; 2011 Apr; 472(7344):486-90. PubMed ID: 21441909
[TBL] [Abstract][Full Text] [Related]
17. Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses.
Ecoeur F; Weiss J; Kaupmann K; Hintermann S; Orain D; Guntermann C
Front Immunol; 2019; 10():577. PubMed ID: 30972071
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003.
Sasaki Y; Odan M; Yamamoto S; Kida S; Ueyama A; Shimizu M; Haruna T; Watanabe A; Okuno T
Bioorg Med Chem Lett; 2018 Dec; 28(22):3549-3553. PubMed ID: 30301676
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
[TBL] [Abstract][Full Text] [Related]
20. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
Hu Y; Shen F; Crellin NK; Ouyang W
Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
